TXG - 10x Genomics, Inc.
NASDAQ
->
Healthcare
->
Health Information Services
Pleasanton,
United States
Type: Equity
TXG price evolution
TXG
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $379.82 | $355.78 | $359.28 | |
| Short term investments | $0.27 | $16.03 | $29.41 | |
| Net receivables | $83.53 | $91.18 | $91.31 | $114.83 |
| Inventory | $94.05 | $88.27 | $83.19 | $73.71 |
| Total current assets | $593.89 | $579.15 | $567.09 | $596.02 |
| Long term investments | ||||
| Property, plant & equipment | $318.34 | $324.16 | $332.34 | $344.93 |
| Goodwill & intangible assets | $21.17 | $20.64 | $21.13 | |
| Total noncurrent assets | $350.51 | $355.82 | $369.12 | |
| Total investments | $0.27 | $16.03 | $29.41 | |
| Total assets | $937.79 | $929.67 | $922.91 | $965.14 |
| Current liabilities | ||||
| Accounts payable | $26.21 | $21.25 | $20.22 | $15.74 |
| Deferred revenue | $27.79 | $24.08 | $21.96 | |
| Short long term debt | $10.82 | $11.13 | $11.52 | |
| Total current liabilities | $121.23 | $111.02 | $108.73 | $127.16 |
| Long term debt | $78.66 | $81.05 | $83.85 | |
| Total noncurrent liabilities | $94.59 | $95.35 | $96.94 | |
| Total debt | $89.48 | $92.18 | $95.37 | |
| Total liabilities | $214.99 | $205.61 | $204.08 | $224.1 |
| Shareholders' equity | ||||
| Retained earnings | -$1418.02 | -$1382.27 | -$1344.37 | -$1284.42 |
| Other shareholder equity | $0.03 | -$0.43 | -$0.46 | -$0.43 |
| Total shareholder equity | $724.06 | $718.83 | $741.04 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $359.28 | $227.35 | $596.07 | $688.64 |
| Short term investments | $29.41 | $210.24 | ||
| Net receivables | $114.83 | $104.21 | $85.25 | $51.21 |
| Inventory | $73.71 | $81.63 | $59.97 | $29.96 |
| Total current assets | $596.02 | $635.03 | $747.59 | $774.37 |
| Long term investments | ||||
| Property, plant & equipment | $344.93 | $359.21 | $230.41 | $119.82 |
| Goodwill & intangible assets | $21.13 | $27.37 | $29.91 | |
| Total noncurrent assets | $369.12 | $393.94 | $271.24 | $154.97 |
| Total investments | $29.41 | $210.24 | ||
| Total assets | $965.14 | $1028.98 | $1018.83 | $929.34 |
| Current liabilities | ||||
| Accounts payable | $15.74 | $21.6 | $17.35 | $4.71 |
| Deferred revenue | $21.96 | $7.87 | $5.34 | $4.47 |
| Short long term debt | $11.52 | $9.04 | $5.13 | $5.94 |
| Total current liabilities | $127.16 | $130.96 | $110.36 | $118.13 |
| Long term debt | $83.85 | $86.14 | $76.85 | $57.04 |
| Total noncurrent liabilities | $96.94 | $92.28 | $90.9 | $72.14 |
| Total debt | $95.37 | $95.18 | $81.98 | $62.98 |
| Total liabilities | $224.1 | $223.24 | $201.26 | $190.27 |
| Shareholders' equity | ||||
| Retained earnings | -$1284.42 | -$1029.32 | -$863.32 | -$805.1 |
| Other shareholder equity | -$0.43 | -$4.33 | $0.02 | -$0.05 |
| Total shareholder equity | $741.04 | $805.74 | $817.57 | $739.07 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $151.65 | $153.1 | $141.01 | $183.98 |
| Cost of revenue | $48.88 | $48.09 | $68.2 | |
| Gross Profit | $106.39 | $104.22 | $92.91 | $115.78 |
| Operating activities | ||||
| Research & development | $62.92 | $68.64 | $65.27 | |
| Selling, general & administrative | $83.04 | $85.77 | $86.13 | |
| Total operating expenses | $147.88 | $145.96 | $154.41 | $170.97 |
| Operating income | -$41.74 | -$61.5 | -$55.19 | |
| Income from continuing operations | ||||
| EBIT | -$37.08 | -$57.8 | -$46.59 | |
| Income tax expense | $1.31 | $0.82 | $2.15 | $2.35 |
| Interest expense | $4.97 | $0 | $0 | $0.01 |
| Net income | ||||
| Net income | -$35.75 | -$37.9 | -$59.95 | -$48.95 |
| Income (for common shares) | -$37.9 | -$59.95 | -$48.95 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $618.73 | $516.41 | $490.49 | $298.85 |
| Cost of revenue | $209.41 | $120.39 | $74.09 | $58.47 |
| Gross Profit | $409.31 | $396.02 | $416.4 | $240.38 |
| Operating activities | ||||
| Research & development | $270.33 | $265.67 | $211.75 | $123.38 |
| Selling, general & administrative | $343.33 | $298.3 | $257.56 | $202.33 |
| Total operating expenses | $674.64 | $563.97 | $468.65 | $774.52 |
| Operating income | -$265.33 | -$167.94 | -$52.25 | -$534.14 |
| Income from continuing operations | ||||
| EBIT | -$248.73 | -$161.5 | -$52.85 | -$532.79 |
| Income tax expense | $6.34 | $4.03 | $4.51 | $8.26 |
| Interest expense | $0.03 | $0.48 | $0.87 | $1.68 |
| Net income | ||||
| Net income | -$255.1 | -$166 | -$58.22 | -$542.73 |
| Income (for common shares) | -$255.1 | -$166 | -$58.22 | -$542.73 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$37.9 | -$59.95 | -$48.95 | |
| Operating activities | ||||
| Depreciation | $10.9 | $11.49 | $11.71 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.49 | $36.13 | $38.92 | |
| Total cash flows from operations | $7.5 | -$15.72 | $25.76 | |
| Investing activities | ||||
| Capital expenditures | -$2.88 | -$2.91 | -$3.45 | |
| Investments | $15.82 | $13.54 | $16.55 | |
| Total cash flows from investing | $18.96 | $11.95 | $10.63 | $13.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.6 | $1.64 | $5.61 | |
| Net borrowings | $5.81 | |||
| Total cash flows from financing | $6.4 | $4.6 | $1.64 | $5.61 |
| Effect of exchange rate | $0.1 | -$0 | -$0.05 | $0.08 |
| Change in cash and equivalents | $38.87 | $24.04 | -$3.5 | $44.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$255.1 | -$166 | -$58.22 | -$542.73 |
| Operating activities | ||||
| Depreciation | $43.62 | $33.01 | $28.25 | $19.02 |
| Business acquisitions & disposals | -$4 | -$5.45 | ||
| Stock-based compensation | $166.95 | $136.85 | $95.96 | $48.63 |
| Total cash flows from operations | -$15.2 | -$33.61 | -$21.37 | -$217.9 |
| Investing activities | ||||
| Capital expenditures | -$48.6 | -$131.66 | -$101.28 | -$36.67 |
| Investments | $183.02 | -$215.23 | ||
| Total cash flows from investing | $133.49 | -$350.89 | -$106.73 | -$38.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $19.48 | $21.23 | $40.33 | $506.01 |
| Net borrowings | -$37.1 | |||
| Total cash flows from financing | $13.67 | $15.82 | $35.3 | $468.91 |
| Effect of exchange rate | -$0.03 | -$0.04 | $0.23 | -$0.46 |
| Change in cash and equivalents | $131.93 | -$368.72 | -$92.57 | $212.15 |
News
Fundamentals
| Market cap | $1.79B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 121.04M |
| Revenue | $629.74M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$182.55M |
| Revenue Q/Q | -1.30% |
| Revenue Y/Y | 6.56% |
| P/E ratio | -9.82 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.85 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.51 |
|---|---|
| ROA | -19.44% |
| ROE | N/A |
| Debt/Equity | 0.30 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.90 |
| Quick ratio | 4.12 |